Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 1,694 trials

Advanced Solid Tumors: TNG462 Treatment Study

We are testing a new treatment called TNG462 for patients with advanced solid tumors that have a specific genetic deletion. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced or Metastatic Solid Tumors with MTAP Deletion>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Perianal Fistulas: Regenerative Cell Therapy Study

We are evaluating a new treatment combining surgery and regenerative cell therapy for people with complex perianal fistulas. The goal is to see if this approach improves healing outcomes.

Perianal Fistula>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Relapsed/Refractory AML: Venetoclax and Decitabine Therapy

We are studying a new combination treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to see if this therapy can help achieve remission and improve safety and recovery outcomes.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

IMC-F106C for Advanced PRAME-Positive Cancers

We are studying a new treatment called IMC-F106C for individuals with advanced PRAME-positive cancers. The trial aims to assess its safety and effectiveness, both alone and with other cancer therapies.

Urothelial CarcinomaNon-Small Cell Lung CancerOvarian Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Wilms Tumor: Metronomic Chemotherapy Study

We are evaluating a new chemotherapy regimen for children and teenagers with relapsed or refractory Wilms tumor. The study aims to assess safety, effectiveness, and quality of life during treatment.

Wilms Tumor6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Alopecia Areata: Baricitinib for Children

We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.

Alopecia Areata6-12 monthsConfirmation phase (III)16-20 visitsStandard MedicinesDermatologyPediatrics

Neuroendocrine Tumors: SAUNA Trial on Somatostatin Analogues

We are studying whether continuing or stopping somatostatin analogues affects survival and quality of life in patients with neuroendocrine tumors after disease progression. This trial aims to provide insights into the best treatment strategies for these patients.

Neuroendocrine Tumors1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Early-Stage Breast Cancer: Long-Term Follow-Up Study

We are examining the long-term health of early-stage breast cancer patients from previous studies. This research will help us understand relapse rates and overall survival.

Early Stage Invasive Breast Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Preeclampsia Intervention 4: Metformin for Preterm Preeclampsia

We are studying whether daily metformin can help prolong pregnancy in women with preterm preeclampsia. We also want to see if it improves outcomes for newborns, like increasing birth weight and reducing time in neonatal care.

Preeclampsia>2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsInternal Medicine

Advanced Solid Tumors: INCB099280 Study

We are testing a new medication for patients with advanced solid tumors who have not yet received immune checkpoint inhibitors. The goal is to evaluate its safety and how well it may control the disease.

Advanced Non-Small Cell Lung CancerAdvanced MelanomaUrothelial Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Melanoma: Tebentafusp Treatment Study

We are studying a new treatment for advanced melanoma in patients who have already been treated. This trial compares tebentafusp alone and with pembrolizumab against standard treatment options to see if it improves survival and quality of life.

Uveal MelanomaMetastatic Malignant MelanomaPreviously Treated Non-Ocular Advanced MelanomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Dermatomyositis and Polymyositis: PF-06823859 Study

We are testing a new medication to see if it helps reduce muscle and skin symptoms in adults with active dermatomyositis or polymyositis. This study compares the new treatment to a placebo to evaluate its effectiveness.

Polymyositis and DermatomyositisConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Laryngeal Cancer: ELOS Study on New Treatment

We are studying whether adding pembrolizumab to standard chemotherapy and radiation helps patients with advanced laryngeal cancer avoid laryngectomy. This trial also examines the impact on swallowing quality and overall survival.

Advanced Laryngeal and Hypopharyngeal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Cancer Study: LY3537982 for KRAS G12C Mutant Tumors

We are testing a new drug, LY3537982, in patients with advanced solid tumors that have a specific genetic mutation. The goal is to see how well it works and how safe it is when used alone or with other cancer treatments.

KRAS G12C-Mutant Advanced Solid TumorsSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Gastroesophageal Reflux Disease in Infants: Diet vs. Medication

We are studying whether a cow's milk-free diet or a medication helps reduce reflux episodes in infants with GERD. Parents will track their baby's symptoms using an app during the trial.

Gastroesophageal Reflux Disease (GERD)Cows' Milk AllergyConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesGastroenterologyPediatrics

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Primary Central Nervous System Lymphoma: MTR² Treatment Study

We are studying a new combination of medications for patients with primary central nervous system lymphoma who cannot receive intensive therapies. The goal is to see if this treatment is effective and safe, and how it affects quality of life.

Primary Central Nervous Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyNeurology